Vaccines: An ongoing promise?

Digestive Diseases

Volumn 19, Issue 2, 2001, Pages 148-157

  Alsahli, Mazen ^a   Farrell, Richard J ^a   Michetti, Pierre ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Helicobacter pylori; Immunization; Vaccines

Indexed keywords

ADHESIN; ADJUVANT; ANTIGEN; BACTERIAL TOXIN; FLAGELLIN; UREASE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION;

EID: 0034851755     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050670     Document Type: Review

References (120)

1. Helicobacter pylori infection and the risk of gastric carcinoma
2. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
3. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease
4. Is gastric lymphoma an infectious disease?
5. Helicobacter pylori and dyspepsia
6. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
7. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population
8. Helicobacter pylori and extra-digestive diseases
9. Immune and inflammatory responses to Helicobacter pylori infection
10. Immunohistochemical detection of Helicobacter pylori in the surface mucous gel layer and its clinicopathological significance
11. Ecology of Helicobacter pylori in the human stomach
12. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects
13. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects
14. Decreased Helicobacter pylori-specific gastric secretory IgA antibodies in infected patients
15. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa
16. Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide
17. Expression of the human cell surface glycoconjugates Lewis x and Lewis y by Helicobacter pylori isolates is related to cagA status
18. Molecular mimicry between Helicobacter pylori and the host
19. Simultaneous expression of type 1 and type 2 Lewis blood group antigens by Helicobacter pylori lipopolysaccharides: Molecular mimicry between H. pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms
20. Antigastric autoantibodies in ferrets naturally infected with Helicobacter mustelae
21. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice
22. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype
23. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa
24. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils
25. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa
26. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism
27. Activation of human phagocyte oxidative metabolism by Helicobacter pylori
28. Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression
29. Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas ligand interactions
30. A small animal model of human Helicobacter pylori active chronic gastritis
31. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
32. Immunisation against gastric infection with Helicobacter species: First step in the prophylaxis of gastric cancer?
33. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
34. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis
35. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice
36. Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice
37. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection
38. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
39. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies
40. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions
41. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load
42. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection
43. Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice
44. Systemic vaccination inducing either Th1 or Th2 immunity protects mice from challenge with H. pylori
45. Replication-defective adenovirus infection reduces Helicobacter felis colonization in the mouse in a gamma interferon- and interleukin-12-dependent manner
46. Influence of pH on metabolism and urease activity of Helicobacter pylori
47. The role of internal urease in acid resistance of Helicobacter pylori
48. +-gated urea channel: The link between Helicobacter pylori urease and gastric colonization
49. Mechanisms of Helicobacter pylori infection: Bacterial factors
50. Urease-negative Helicobacter pylori isolates from gastrointestinal mucosa of patients with peptic ulcer
51. Immunization against natural Helicobacter pylori infection in nonhuman primates
52. Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta)
53. Helicobacter pylori motility
54. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes
55. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori
56. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging
57. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin
58. Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue
59. Isolation and characterisation of putative adhesins from Helicobacter pylori with affinity for heparan sulphate proteoglycan
60. Relation of Helicobacter pylori to the human gastric mucosa in chronic gastritis of the antrum
61. Mucus and H. pylori
62. Peroral immunization with Helicobacter pylori adhesin protein genetically linked to cholera toxin A2B subunits
63. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori
64. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion
65. Detoxification of the Helicobacter pylori cytotoxin
66. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
67. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
68. Therapeutic immunisation against Helicobacter infection
69. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice
70. Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori
71. Lack of protection following immunisation with H. pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori
72. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate
73. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor
74. Protection of BALB/c mice against experimental Helicobacter pylori infection by oral immunisation with H. pylori heparan sulphate-binding proteins coupled to cholera toxin beta-subunit
75. Catalase, a novel antigen for Helicobacter pylori vaccination
76. The complete genome sequence of the gastric pathogen Helicobacter pylori
77. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
78. Identification of protein vaccine candidates from Helicobacter pylori using a preparative two-dimensional electrophoretic procedure and mass spectrometry
79. Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates
80. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling
81. New strategies for using mucosal vaccination to achieve more effective immunization
82. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity
83. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
84. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
85. Site-directed mutagenic alteration of potential active-site residues of the A subunit of Escherichia coli heat-labile enterotoxin: Evidence for a catalytic role for glutamic acid 112
86. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
87. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis
88. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
89. Promotion of ulcerative duodenitis in young ferrets by oral immunization with Helicobacter mustelae and muramyl dipeptide
90. Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles
91. Immune responses to ISCOM® formulations in animal and primate models
92. Systemic immunization with urease protects mice against Helicobacter pylori infection
93. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B
94. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits
95. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response
96. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice
97. DNA immunization decreases the level of infection in the felis-mouse model, irrespective of the titer of specific antibodies
98. Generation of a monoclonal antibody to a defined portion of the Helicobacter pylori vacuolating cytotoxin by DNA immunization
99. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice
100. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets
101. Helicobacter mustelae-associated gastritis in ferrets: An animal model of Helicobacter pylori gastritis in humans
102. Helicobacter mustelae-induced gastritis and elevated gastric pH in the ferret (Mustela putorius furo)
103. Characterization and presumptive identification of Helicobacter pylori isolates from rhesus monkeys
104. Diagnosis of Helicobacter pylori infection in a colony of rhesus monkeys (Macaca mulatta)
105. Natural gastric infection with Helicobacter pylori in monkeys: A model for spiral bacteria infection in humans
106. Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates
107. Gastric injury and invasion of parietal cells by spiral bacteria in rhesus monkeys: Are gastritis and hyperchlorhydria infectious diseases?
108. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
109. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
110. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection
111. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
112. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection
113. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
114. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers
115. Helicobacter pylori vaccines and mechanisms of effective immunity: Is mucus the key?
116. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: Evidence of protection in a mouse model of gastric infection
117. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis
118. Urease-based mucosal immunization against Helicobacter heilmannii infection induces corpus atrophy in mice
119. Challenge model for H. pylori infection in human volunteers
120. Quantitative and bioluminescent assay to measure efficacy of conventional and DNA vaccinations against Helicobacter pylori